CU6 — Clarity Pharmaceuticals Share Price
Last trade - 00:00- AU$731.97m
- AU$693.98m
- AU$11.66m
- 51
- 13
- 92
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.79 | ||
| Price to Tang. Book | 13.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 62.03 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.08% | ||
| Return on Equity | -45.33% | ||
| Operating Margin | -257.71% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | 2.9 | 3.29 | 6.55 | 11.66 | 5 | 7 | 59.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 8th, 2010
- Public Since
- August 25th, 2021
- No. of Shareholders
- 2,011
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 271,098,503
- Address
- 4 Cornwallis Street, EVELEIGH, 2015
- Web
- https://www.claritypharmaceuticals.com/
- Phone
- +61 292094037
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for CU6
Similar to CU6
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:05 UTC, shares in Clarity Pharmaceuticals are trading at AU$2.70. This share price information is delayed by 15 minutes.
Shares in Clarity Pharmaceuticals last closed at AU$2.70 and the price had moved by +292.52% over the past 365 days. In terms of relative price strength the Clarity Pharmaceuticals share price has outperformed the ASX All Ordinaries Index by +265.62% over the past year.
The overall consensus recommendation for Clarity Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Clarity Pharmaceuticals does not currently pay a dividend.
Clarity Pharmaceuticals does not currently pay a dividend.
Clarity Pharmaceuticals does not currently pay a dividend.
To buy shares in Clarity Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$2.70, shares in Clarity Pharmaceuticals had a market capitalisation of AU$731.97m.
Here are the trading details for Clarity Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CU6
Based on an overall assessment of its quality, value and momentum Clarity Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Clarity Pharmaceuticals is AU$3.37. That is 24.67% above the last closing price of AU$2.70.
Analysts covering Clarity Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.13 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clarity Pharmaceuticals. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +126.18%.
As of the last closing price of AU$2.70, shares in Clarity Pharmaceuticals were trading +67.71% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Clarity Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$2.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Clarity Pharmaceuticals' directors